Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

OKUTURLAR, YILDIZ; Gunaldi, Meral; Kocoglu, Hakan; Hursitoglu, Mehmet; GEDİKBAŞI, Asuman; Acarer, Didem; Harmankaya, Ozlem; Kumbasar, Abdulbaki

doi:10.4103/0973-1482.235355

Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

OKUTURLAR Y. , Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., ...More

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.14, 2018 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 14
Publication Date: 2018
Doi Number: 10.4103/0973-1482.235355
Title of Journal : JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Keywords: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK

Abstract

Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.